Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Gossamer Bio submitted its first NDA to the FDA in September 2026 for seralutinib to treat pulmonary arterial hypertension. The filing relies on the Phase 3 PROSERA study plus confirmatory evidence from the Phase 2 TORREY study; the FDA's June 2026 Pre-NDA meeting minutes characterized the degree of statistical significance and magnitude of treatment effect as review issues rather than filing issues.
Key figures
- Drug Name
- seralutinib
- Phase Of Trial
- Phase 3
- First nda submission
- Yes
- Pre nda meeting date
- June 2026
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.